Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis in a study conducted by Eric L. Simpson, MD, and colleagues. The study found that more patients treated with roflumilast vs. vehicle achieved a validated IGA-AD score of 0/1, with minimal application site irritation reported. The once-daily nonsteroidal cream addressed several unmet needs in the treatment of atopic dermatitis, showing improvement in reducing pruritus and favorable safety and tolerability. The study included 1,337 patients and concluded that roflumilast has the potential to substantially improve treatment for atopic dermatitis.
Source link
Roflumilast cream 0.15% addresses unmet needs of adults, children with atopic dermatitis
